|Articles|February 1, 2009
Triple therapy AMD trial to continue
The Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) is to continue as planned, following promising interim results and the positive recommendations of the independent Data and Safety Monitoring Committee.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
How Digital Workflow Boosted my Confidence and Elevated Premium Patient Rates in Cataract Surgery
2
From skepticism to clarity and focus: A family’s PRESBYOND experience
3
Celltrion’s EYLEA-referencing biosimilar, EYDENZELT, receives Canadian approval
4
Evolving Practice In Retinal Care A Question Of Control
5











































